SYNTHESIS OF 3-(\$-D-RIBOFURANOSYL)-5,7-DIHYDROXY-1H-PYRAZOLO/4,3-d/PYRIMIDINE

M. Bobek, J. Farkaš and F. Šorm

Institute of Organic Chemistry and Biochemistry,

Czechoslovak Academy of Sciences, Prague

(Received in UK 15 September 1970; accepted for publication 14 October 1970)

As a part of a study on nucleoside antibiotics we have prepared 3-(β -D-ribofuranosyl)-5,7-dihydroxy-lH-pyrazolo/4,3-d/pyrimidine¹ ("oxoformycin", Ia) which has been hitherto available by biological oxidation of formycin². The synthesis of Ia was accomplished by the procedure described previously³ in the preparation of 3-hydroxymethyl- and 3-(2-tetrahydrofuryl)-5,7-dihydroxy-lH-pyrazolo/4,3-d/pyrimidine. (A part of the mentioned reaction sequence was applied by Goodman⁴ in the synthesis of 3-(2,3-0-isopropylidene- β -DL-erythrofuranosyl)-4,7-dihydroxy-lH-pyrazolo/3,4-d/pyridazine.)

3,4,6-Tri-O-benzyl-1-deoxy-1-ureido-2,5-anhydro-D-allitol (II) described earlier⁵, was converted into N-nitroso derivative III according to the procedure of Kirmse⁶. $C_{28}H_{31}N_3O_6$; λ max in ethanol 213 nm and 236 nm (log ε 4.17 and 3.66, resp.); ir in carbon tetrachloride: ν (C=O) 1743 cm⁻¹, ν (NH₂) 3530 cm⁻¹, 3410 cm⁻¹, ν (N=O) 1500 cm⁻¹. The ethereal solution of III was treated with 30% aqueous potassium hydroxide at O^0 to give a yellow solution

4612 No.52

of diazomethane derivative IV to which, in turn, dimethyl acetylenedicarboxylate was added at 10° . After decolorination of the reaction mixture (within 5 minutes) dimethyl 3-(2,3,5-tri-O-benzyl- β -D-ribofuranosyl)-pyrazole-4,5-dicarboxylate (V) was isolated by silica gel chromatography (benzene - ethyl acetate mixture 4:1). $C_{33}H_{34}N_{2}O_{8}$; $[\alpha]_{D}^{25}$ +110.4° (c C.5 in chloroform); Amax in ethanol 213 nm ($\log \varepsilon$ 4.31); ir in carbon tetrachloride: ν (C=0) 1746 cm⁻¹, 1741 cm⁻¹, ν (NH) 324C cm⁻¹. On treatment of V with methanolic ammonia at 25°, methyl 3-(2,3,5-tri-O-benzyl- β -D-ribofuranosyl)-5-carbamoylpyrazole-4-carboxylate (VI) was obtained. (The structure of VI was assigned by analogy with the reported course of ammonolysis of dimethyl pyrazole-4,5-carboxylate.) $C_{32}H_{33}N_{3}O_{7}$; $\ell\alpha/D^{25}$ +71.3° (c C.5 in chloroform); ℓ max in ethanol 216 nm and

 $R = 2,3,5-tri-O-benzyl-\beta-D-ribofuranosyl$

300 nm (log & 4.22 and 2.73, resp.); ir in carbon tetrachloride: ν (C=C) 1693 cm⁻¹, 1679 cm⁻¹. Hydrazinolysis of the methoxycarbonyl group of VI occurred under reflux in ethanolic solution to yield 3-(2,3,5-tri-0-benzyl- β -D-ribo-furanosyl)-5-carbamoylpyrazole-4-carboxylic hydrazide (VII). $C_{31}H_{33}N_{5}O_{6}i$ $/\alpha J_{D}^{25}$ +178.2° (c 0.5 in chloroform); λ max in ethanol 214 nm (log ε 4.4C); ir in carbon tetrachloride: ν (C=C) 1679 cm⁻¹, 1642 cm⁻¹. Chromatographical monitoring of the hydrazinolysis of VI revealed that VII reacted subsequently with hydrazine under the formation of 3-(2,3,5-tri-0-benzyl- β -D-ribofuranosyl)-pyrazole-4,5-dicarboxylic hydrazide (VIII) which was obtained on the preparative scale in a high yield by treatment of V with hydrazine hydrate in ethanolic solution. $C_{31}H_{34}N_{6}O_{6}$; m.p. 158-159.5° from ethanol; $/\alpha/D_{0}^{25}$ +183.4° (c 0.5 in

chloroform); .1 max in ethanol 214 nm (log & 4.39); ir in chloroform : $\nu(\text{C}=0)$ 1664 cm⁻¹, $\nu(\text{NH})$ 3420 cm⁻¹. VIII was cyclised into 3-(2,3,5-tri-C-benzyl- β -D-ribofuranosyl)-4,7-dihydroxy-lH-pyrazolo/3,4-d/pyridazine (IXb) by treatment with 0.1 M hydrochloric acid in 70% ethanol at 80°. $C_{31}H_{30}N_{4}C_{6}$; $/\alpha/_{D}^{25}$ +173.0° (c 0.5 in chloroform); λ max in ethanol 213 nm and 265 nm (log & 4.36 and 3.74, resp.); ir in carbon tetrachloride: $\nu(\text{C}=0)$ 1652 cm⁻¹. After hydrogenolytical removal of benzyl groups over palladium on barium sulphate catalyst, IXb afforded the free C-nucleoside IXa as a crystalline substance (from 50% ethanol) melting at 255-260° (dec.). $C_{10}H_{12}N_{4}C_{6}$; $/\alpha/_{D}^{25}$ +14.4° (c C.5 in water); λ max in 0.1 M HCl 266 nm (log & 3.75); λ max in C.C5 M Na(H 216 nm and 276 nm (log & 4.29 and 3.85, resp.); nmr in DMSO-d₆ with 1% CH₃CO₂D, internal tetramethylsilane, λ in ppm: 5.02 (d, $J_{1,2}$ ' 7.0 Hz, H_{1} '); 4.28 (q, $J_{2,1}$ ' 7.0 Hz, $J_{2,3}$ ' 5.5 Hz, H_{2}); 4.04 (q, $J_{3,2}$ ' 5.5 Hz, $J_{3,4}$ ' 3.5 Hz, H_{3}); 3.88 (q, $J_{4,3}$ ' = $J_{4,5}$ ' a = $J_{4,5}$ ' b 3.5 Hz, H_{4}); 3,63 (q, J_{5a} ,4' 3.5 Hz, J_{gem} 12.0 Hz, H_{5b}).

The Curtius degradation of VII as carried out as follows: VII (350 mg) in 10 ml of dimethylformamide was treated at 00 with 1 ml of 2 M HCl and after 5 minutes with 1 ml of 2 M sodium nitrite. After standing at 00 for two hours, the reaction mixture was worked up by diluting with ice water and extracting with ether. Ethereal extracts were concentrated in vacuo at 10°. The residual oil was refluxed in tert. butanol for two hours. Chromatographical purification on silica gel in benzene - ethyl acetate mixture (1:1) of the sirupy material obtained after evaporation of tert. butanol, gave 142 mg of a solid fraction which was recrystalized from ethanol to give 94 mg of 3-(2,3,5tri-O-benzyl-β-D-ribofuranosyl-5,7-dihydroxy-lH-pyrazolo/4,3-d/pyrimidine (Ib). $C_{31}H_{30}N_4O_6$; m.p. 192-193.5° from ethanol; $(\alpha f_D^{25} - 23.0^\circ)$ (c 0.2 in chloroform); A max in ethanol 288 nm (log ε 3.76); ir in chloroform: ν (C=0) 1694 cm⁻¹, 1710 cm⁻¹, ν (NH) 3385 cm⁻¹, 3430 cm⁻¹. The mass spectrum of Ib exhibits a molecular peak at m/e 554 and an intense peak at B+30 (m/e 181) which is characteristic for fragmentation of C-nucleosides8. Using the sodium-liquid ammonia procedure for removal of benzyl groups, Ib (46.1 mg) was converted * Recorded with a Varian HA 100 at 100 MHz.

to 19.0 mg of the free C-nucleoside Ia. $C_{10}H_{12}N_4O_6$; m.p. 284-285° (dec.) from water; (m.p. reported for "oxoformycin" 274°); λ max in 0.1 M HCl 288 nm (log ϵ 3.76), λ max in 0.05 NaOH 226 nm, 250 nm, 303 nm (log ϵ 4.43, 3.81 and 3.72, resp.); ir in KBr pellet is identical with that reported by Umezawal for "oxoformycin".

Compound Ib appears as a versatile intermediate for the synthesis of formycin analogues.

Satisfactory analytical data were obtained for all compounds where the empirical formula is given.

REFERENCES

- M. Ishizuka, T. Sawa, G. Koyama, T. Takeuchi and H. Umezawa,
 J. Antibiotics (Tokyo) 21, 1 (1968).
- 2. J.J. Fox, K.A. Watanabe and A. Bloch, Progress in Nucleic Acid Research and Molecular Biology 5, 251 (1966).
- 3. M. Sprinzl, J. Farkaš and F. Šorm, Tetrahedron Letters 289 (1969).
- 4. E.M. Acton, K.J. Ryan and L. Goodman, Chem. Commun. 313 (1970).
- 5. M. Bobek and J. Farkaš, Collection Czech. Chem. Commun. 34, 1684 (1969).
- 6. W. Kirmse and M. Buschhoff, Chem. Ber. 100, 1491 (1967).
- 7. R.G. Jones and C.W. Whitehead, J. Crg. Chem. 20, 1342 (1965).
- 8. L.B. Townsend and R.K. Robins, J. Heterocyclic Chem. 6, 459 (1969).
- 9. E.J. Reist, V.J. Bartuska and L. Goodman, J. Crg. Chem. 29, 3725 (1964).